Radioactive drug plus immunotherapy shows promise for tough lung cancer

NCT ID NCT07413042

Recruiting now Disease control Sponsor: Peking University Cancer Hospital & Institute Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase study tests a combination of a radioactive drug ([225Ac]Ac-DOTATATE) and an immunotherapy (tislelizumab) as maintenance therapy for people with extensive-stage small cell lung cancer that has a specific marker (SSTR). The goal is to see if this combination is safe and can help keep the cancer from growing after initial treatment. About 24 adults who have finished their first round of standard chemotherapy will participate.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SCLC, EXTENSIVE STAGE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SCLC, EXTENSIVE STAGE

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Peking University Cancer Hospital & Institute
RECRUITING

Beijing, Beijing Municipality, 100000, China

Contact Phone: •••-•••-•••• Email: •••••@•••••